Percutaneous approach to detect cytokines in inflammatory skin diseases

Research for the development of percutaneous method to detect cytokines in inflammatory skin diseases - Percutaneous approach to detect cytokines in inflammatory skin diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs062180083

Enrollment

Registered

2019-03-20

Start date

2019-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory skin disease

Interventions

We develop skin-blotting to measure the amounts of percutaneously expressed cytokines by putting the nitrocellulose membrane on the lesional skin of the inflammatory skin diseases, and investigate if

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inflammatory skin diseases presenting erythematous plaque with slight scaling. Such as bullous pemphigoid, prurigo chronica multiformis, erythema nodosum, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, toxicoderma.

Exclusion criteria

Exclusion criteria: 1. History of atopic dermatitis 2. Subjects with systemic infectious diseases 3. Defined history of allergic contact dermatitis from adhesive tapes. 4. Other judged as being inappropriate for the study by the investigators.

Design outcomes

Primary

Measure	Time frame
To investigate if there is correlation between symptoms of each inflammatory skin diseases and the amounts of cytokines detected percutaneously with skin blotting.	—

Secondary

Measure	Time frame
Evaluation of skin blotting for the early diagnosis of severe erythema multiforme such as Stevens-Johnson syndrome, toxic epidermal necrolysis.	—

Contacts

Public ContactSayama Koji

Ehime University Hospital

sayama@m.ehime-u.ac.jp+81-89-960-5350

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026